Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00785941 · ClinicalTrials.gov registry record · Phase 1

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

A Phase 1 study of Advanced Solid Tumors, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT00785941 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Eli Lilly and Company. The registered enrollment target is 16 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00785941, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if IMC-A12 is safe for patients, and also to determine the best dose of IMC-A12 to give to patients.

Conditions Studied

Advanced Solid Tumors

Interventions

  • BIOLOGICAL IMC-A12

Study Locations (1)

Tennessee

  • ImClone Investigational Site - Nashville

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2006-04
Est. Completion 2007-11
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00785941

The ClinicalTrials.gov registry entry for NCT00785941 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (92% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which IMC-A12 is the first listed.

NCT00785941 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00785941 about?

NCT00785941 is a clinical study titled "A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available". The purpose of this study is to determine if IMC-A12 is safe for patients, and also to determine the best dose of IMC-A12 to give to patients.

What is the current status of trial NCT00785941?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2006-04. Estimated completion is 2007-11.

What conditions does trial NCT00785941 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT00785941?

The interventions under investigation include: IMC-A12 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00785941?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00785941 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.